Work

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

Year: 2018

Type: article

Abstract: Clinical Practice Points•Hepatocyte growth factor receptor (MET) exon 14 (METex14) skipping mutations are an emerging therapeutic target in non–small-cell lung cancer.•Neoadjuvant treatment with the MET tyrosine kinase inhibitor crizotinib in a locally advanced, unresectable METex14-mutated lung adenocarcinoma led to conversion to resectable status with pathologic complete response.•Neoadjuvant treatment with targeted therapies might provide an alternative to neoadjuvant chemotherapy for patients with oncogenic driver mutations. •Hepatocyte growth factor receptor (MET) exon 14 (METex14) skipping mutations are an emerging therapeutic target in non–small-cell lung cancer.•Neoadjuvant treatment with the MET tyrosine kinase inhibitor crizotinib in a locally advanced, unresectable METex14-mutated lung adenocarcinoma led to conversion to resectable status with pathologic complete response.•Neoadjuvant treatment with targeted therapies might provide an alternative to neoadjuvant chemotherapy for patients with oncogenic driver mutations.

Source: Clinical Lung Cancer

DOI: 10.1016/j.cllc.2018.11.003